Fundraising Fox

Ridgeback Capital

Crossover fund

Miami · Seed–Late Stage · 1 people tracked

Fox Verdict
Sign up to see your fit

Investment thesis

Healthcare innovation requires extended timelines and patient capital for companies to develop transformative medicines addressing unmet medical needs. The firm invests across both public and private markets in biopharmaceutical companies, supporting research and development of novel therapies.

Invests inBiotechHealthtechMiamiNew York

Source: firm website, verified Jul 21, 2026.

Stage
Seed–Late Stage
HQ
Miami, US
Founded
2006
AUM
$171.5M
Tracked investments
18

Team · 1 people

from the firm's website
Wayne Holman· Founder and CEO

Physician and founder of Ridgeback Capital with over two decades of biopharma investment experience, having funded more than 100 companies. Co-founder of Ridgeback Biotherapeutics and graduate of NYU School of Medicine with an economics degree from Yale. Serves as Clinical Professor at NYU Langone Health and holds trustee positions at NYU Langone and University of Miami.

What they invest in

from 4 of 18 portfolio companies

Biotech ×4Medical Devices ×4Healthtech ×3Digital Health ×1

HQs:United States×3

Investments · 18 tracked

founders shown can be your intro path
Adaptimmuneadaptimmune.com

Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.

BiotechHealthtechMedical Devices

ALDRalderbio.com
BMRNbmrn.com
Cellectiscellectis.comin𝕏
CLVSclovisoncology.com
CV Therapeuticsgilead.comin𝕏

Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries. The company combines scientific rigor with global partnerships and licensing programs to expand access to medicines worldwide.

BiotechDigital HealthHealthtechMedical DevicesFoster City, US

EPZMepizyme.com
Fibrogenfibrogen.comin𝕏
GNFTgenfit.comin
ICPTinterceptpharma.comin𝕏
IRWDironwoodpharma.comin𝕏
Macrogenics Incmacrogenics.comin

MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer patients, including oncology, hematology, and autoimmune applications. The company uses platform technologies such as antibody-drug conjugates, bispecific checkpoint antibodies, and T-cell engagers.

BiotechMedical Devices

Regeneron NASDAQ: REGN www.regeneron.comregeneron.com

Regeneron discovers, develops, and manufactures biologics and genetic medicines for treating serious diseases including metabolic disorders, ophthalmology conditions, and rare diseases. The company serves patients globally through clinical trials and commercial pharmaceutical products.

BiotechHealthtechMedical DevicesTarrytown, US

SGMOsangamo.comin𝕏
TSROtesarobio.com
UTHRunither.com

Frequently asked questions

What stage does Ridgeback Capital invest at?
Ridgeback Capital invests at the Seed, Late Stage stages.
What sectors does Ridgeback Capital focus on?
Ridgeback Capital focuses on Biotech, Healthtech.
Where is Ridgeback Capital located?
Ridgeback Capital is headquartered in Miami, US.

Similar investors

Andreessen Horowitz

a16z is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz that invests in seed through growth-stage technology companies across multiple sectors including AI, healthcare, consumer, crypto, enterprise, fintech, and gaming. The firm manages over $100 billion in assets and operates a distinctive platform model with a large team of operators supporting founders throughout their journey.

B Capital Group

B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.

Bessemer Venture Partners

Bessemer Venture Partners is a venture capital firm with a 50-year history supporting entrepreneurs in building enduring companies globally. The firm draws on deep operational expertise and advisory relationships to support portfolio companies through their growth journey.

DCVC (Data Collective)

DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.

GV (Google Ventures)

GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.

Featured in lists